317 related articles for article (PubMed ID: 20501593)
1. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.
Bernardo GM; Lozada KL; Miedler JD; Harburg G; Hewitt SC; Mosley JD; Godwin AK; Korach KS; Visvader JE; Kaestner KH; Abdul-Karim FW; Montano MM; Keri RA
Development; 2010 Jun; 137(12):2045-54. PubMed ID: 20501593
[TBL] [Abstract][Full Text] [Related]
2. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
3. Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.
Cornelissen LM; Henneman L; Drenth AP; Schut E; de Bruijn R; Klarenbeek S; Zwart W; Jonkers J
J Mammary Gland Biol Neoplasia; 2019 Dec; 24(4):305-321. PubMed ID: 31729597
[TBL] [Abstract][Full Text] [Related]
4. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 in breast cancer.
Nakshatri H; Badve S
Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
[TBL] [Abstract][Full Text] [Related]
6. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
[TBL] [Abstract][Full Text] [Related]
7. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
9. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
10. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
McCune K; Mehta R; Thorat MA; Badve S; Nakshatri H
Oncol Rep; 2010 Nov; 24(5):1233-9. PubMed ID: 20878115
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice.
Feng Y; Manka D; Wagner KU; Khan SA
Proc Natl Acad Sci U S A; 2007 Sep; 104(37):14718-23. PubMed ID: 17785410
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
14. FOXA1: a transcription factor with parallel functions in development and cancer.
Bernardo GM; Keri RA
Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
17. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
18. Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R; Abou Ziki R; Kassem L; Luo Y; Malbeteau L; Gherardi S; Corbo L; Bertolino P; Bachelot T; Treilleux I; Zhang CX; Le Romancer M
Breast Cancer Res Treat; 2021 Dec; 190(3):389-401. PubMed ID: 34561764
[TBL] [Abstract][Full Text] [Related]
19. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
20. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
